Article

Deconstructing Stem Cell Tumorigenicity: A Roadmap to Safe Regenerative Medicine

Department of Cell Biology and Human Anatomy & Stem Cell Program, University of California Davis School of Medicine, Sacramento, CA, USA.
Stem Cells (Impact Factor: 7.7). 05/2009; 27(5):1050-6. DOI: 10.1002/stem.37
Source: PubMed

ABSTRACT Many of the earliest stem cell studies were conducted on cells isolated from tumors rather than from embryos. Of particular interest was research on embryonic carcinoma cells (EC), a type of stem cell derived from teratocarcinoma. The EC research laid the foundation for the later discovery of and subsequent work on embryonic stem cells (ESC). Both ESC isolated from the mouse (mESC) and then later from humans (hESC) shared not only pluripotency with their EC cousins, but also robust tumorigenicity as each readily form teratoma. Surprisingly, decades after the discovery of mESC, the question of what drives ESC to form tumors remains largely an open one. This gap in the field is particularly serious as stem cell tumorigenicity represents the key obstacle to the safe use of stem cell-based regenerative medicine therapies. Although some adult stem cell therapies appear to be safe, they have only a very narrow range of uses in human disease. Our understanding of the tumorigenicity of human induced pluripotent stem cells (IPSC), perhaps the most promising modality for future patient-specific regenerative medicine therapies, is rudimentary. However, IPSC are predicted to possess tumorigenic potential equal to or greater than that of ESC. Here, the links between pluripotency and tumorigenicity are explored. New methods for more accurately testing the tumorigenic potential of IPSC and of other stem cells applicable to regenerative medicine are proposed. Finally, the most promising emerging approaches for overcoming the challenges of stem cell tumorigenicity are highlighted.

2 Followers
 · 
102 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Currently, lung disease and major airway trauma constitute a major global healthcare burden with limited treatment options. Airway diseases such as chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF) have been identified as the fifth highest cause of mortality worldwide and are estimated to rise to fourth place by 2030. Alternate approaches and therapeutic modalities are urgently needed to improve clinical outcomes for chronic lung disease. This can be achieved through tissue engineering of the respiratory tract. Interest is growing in the use of airway tissue engineered constructs as both a research tool to further our understanding of airway pathology, validate new drugs and pave the way for novel drug therapies, and also as regenerative medical devices or as an alternative to transplant tissue. This review provides a concise summary of the field of respiratory tissue engineering to date. An initial overview of airway anatomy and physiology is given, followed by a description of the stem cell populations and signalling processes involved in parenchymal healing and tissue repair. We then focus on the different biomaterials and tissue engineered systems employed in upper and lower respiratory tract engineering, and give a final perspective of the opportunities and challenges facing the field of respiratory tissue engineering.
    Tissue Engineering Part B Reviews 01/2015; DOI:10.1089/ten.TEB.2014.0525 · 4.64 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Parkinson’s disease (PD) is the second most common neurodegenerative brain disorder which is around 1.5 times more common in men than in women. Currently, drug medications, surgery, and lifestyle changes are common approaches to PD, while all of them focused on reducing the symptoms. Therefore, degenerative med i-cine based on stem cell (SC) therapies has raised a promising hope. Various types of SCs have been used in basic and experimental studies relevant to PD, including embryonic pluripotential stem cells, mesenchymal (MSCs) and induced pluripotent SCs (iPSCs). MSCs have several advantages over other counterparts. They are easily accessible which can be obtained from various tissues such as bone marrow, adipose tissue, peripheral blood, etc. with avoiding ethical problems. Therefore, MSCs is attractive clinically because there are no related ethical and immunological concerns . Further studies are needed to answer some crucial questions about the different issues in SC therapy. Accordingly, SC-based therapy for PD also needed more complementary evaluation in both basic and clinical study areas.
    Medical journal of the Islamic Republic of Iran 01/2015; 29(168).
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Advances of regenerative medicine in the therapy of type 1 di abetes mellitus. І. Sources of b-cell production (literature review) (part 2) M.D. Tronko, I.P. Pasteur State institution «V.P. Komisarenko Institute of Endocrinology and Metabolism, Natl Acad. Med. Sci. of Ukraine» Summary. Modern scientific data are presented in the review, on the advances of regenerative medicine in the search for sources generating insulin-producing cells for the therapy of type 1 diabetes mellitus. Keywords: type 1 diabetes mellitus, stem cells, insulin-producing cells.

Preview (2 Sources)

Download
0 Downloads
Available from